AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27394144 — intervention group
Group type: EXPERIMENTAL
Intervention: Knot-tying suture technique
Number of subjects: 40
Study 27394144 — intervention group
Group type: COMPARATOR
Intervention: Knotless suture anchor technique
Number of subjects: 40
Study 23359781 — intervention group
Group type: EXPERIMENTAL
Intervention: isoosmolar nonionic dimer contrast medium
Number of subjects: 38
Study 23359781 — intervention group
Group type: COMPARATOR
Intervention: low-osmolar nonionic monomer contrast medium
Number of subjects: 38
Study 22092271 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal, no exercise
Number of subjects: 40
Study 22092271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal, postprandial exercise
Number of subjects: 40
Study 22092271 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal, no exercise
Number of subjects: 40
Study 22092271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal, postprandial exercise
Number of subjects: 40
Study 21186923 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil (once daily)
Number of subjects: 20
Study 21186923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21186923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (modafinil and placebo)
Number of subjects: 20
Study 16934861 — intervention group
Group type: EXPERIMENTAL
Intervention: Party drug use (alcohol, cannabis, ecstasy, cocaine)
Number of subjects: 302
Study 16934861 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of substance use
Number of subjects: 302
Study 16934861 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and social problems related to party drug use
Number of subjects: 302
Study 16934861 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptiveness to harm reduction measures
Number of subjects: 302
Study 16934861 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for prevention personnel
Number of subjects: 302
Study 15868347 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential group living environment
Number of subjects: 12
Study 12063485 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation
Number of subjects: 15
Study 12063485 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 15
Study 10218040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS)-free dentifrice
Number of subjects: 47
Study 10218040 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulfate (SLS) dentifrice
Number of subjects: 47
Study 9430602 — intervention group
Group type: EXPERIMENTAL
Intervention: Globin digest 1 g
Number of subjects: 22
Study 9430602 — intervention group
Group type: EXPERIMENTAL
Intervention: Globin digest 4 g
Number of subjects: 22
Study 1907551 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐induced hypoglycaemia with concomitant alpha‐adrenoceptor blockade
Number of subjects: 7
Study 1907551 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin‐induced hypoglycaemia with total autonomic blockade (alpha‐adrenoceptor blockade combined with beta‐adrenoceptor blockade and atropine)
Number of subjects: 7
Study 1907551 — intervention group
Group type: COMPARATOR
Intervention: Insulin‐induced hypoglycaemia without any autonomic blockade
Number of subjects: 7
Study 7166137 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 556
Study 7166137 — intervention group
Group type: COMPARATOR
Intervention: Street heroin
Number of subjects: 556
Study 30659410 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg daily
Number of subjects: 0
Study 30659410 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg weekly
Number of subjects: 0
Study 30659410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 28637881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal baseline physical activity
Number of subjects: 1751
Study 28637881 — intervention group
Group type: COMPARATOR
Intervention: Intermediate baseline physical activity
Number of subjects: 1751
Study 28637881 — intervention group
Group type: COMPARATOR
Intervention: Poor baseline physical activity
Number of subjects: 1751
Study 24215227 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing
Number of subjects: 57
Study 24215227 — intervention group
Group type: COMPARATOR
Intervention: Unadapted motivational interviewing
Number of subjects: 57
Study 21554143 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate plus alfacalcidol (combination therapy)
Number of subjects: 2164
Study 21554143 — intervention group
Group type: COMPARATOR
Intervention: Alendronate alone (monotherapy)
Number of subjects: 2164
Study 19994693 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6)
Number of subjects: 100
Study 19994693 — intervention group
Group type: COMPARATOR
Intervention: Control group (tape covering without acupuncture)
Number of subjects: 100
Study 17237735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) use
Number of subjects: 202638
Study 17237735 — intervention group
Group type: EXPERIMENTAL
Intervention: Current users of HT
Number of subjects: 202638
Study 15017896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, day first, and Gemcitabine 1250 mg/m2, day 8, every 3 weeks, total 3 cycles plus fractionated radiation therapy (40-46 Gy) for stage IIIa (N2) and IIIb patients.
Number of subjects: 88
Study 15017896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 plus Gemcitabine 1250 mg/m2, every three weeks, total 4 cycles without fractionated radiation therapy for stage IV patients.
Number of subjects: 88
Study 11698931 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy; specific strains not mentioned, dosage and duration not specified.
Number of subjects: 0
Study 11698931 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no specific control intervention mentioned.
Number of subjects: 0
Study 9812566 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified human leucocytic interferon-alpha
Number of subjects: 23
Study 9812566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 8131152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 8131152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 0
Study 8131152 — intervention group
Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 0
Study 2887304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 0
Study 2887304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29405540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671
Study 29405540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study 29405540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin with Acarbose
Number of subjects: 14671
Study 27859588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 61
Study 27859588 — intervention group
Group type: COMPARATOR
Intervention: Client-centered therapy
Number of subjects: 61
Study 27859588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy and Client-centered therapy
Number of subjects: 61
Study 24947717 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy at discharge (n = 6,873)
Number of subjects: 8510
Study 24947717 — intervention group
Group type: COMPARATOR
Intervention: No-beta-blocker therapy at discharge (n = 1,637)
Number of subjects: 8510
Study 24947717 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy after propensity-score matching (n = 1,325)
Number of subjects: 8510
Study 22737708 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg once daily for 6 weeks
Number of subjects: 0
Study 22737708 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol
Number of subjects: 0
Study 22737708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20236696 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 20236696 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 18195071 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA C plus NYVAC C
Number of subjects: 40
Study 18195071 — intervention group
Group type: COMPARATOR
Intervention: NYVAC C alone
Number of subjects: 40
Study 15718059 — intervention group
Group type: EXPERIMENTAL
Intervention: STX plus attendance contracting and prompting (CP)
Number of subjects: 102
Study 15718059 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (STX)
Number of subjects: 102
Study 12766100 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy food choices meal plan (HFC)
Number of subjects: 648
Study 12766100 — intervention group
Group type: COMPARATOR
Intervention: Exchange-based meal plan (EXCH)
Number of subjects: 648
Study 10561182 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vincristine, dactinomycin, cyclophosphamide, doxorubicin)
Number of subjects: 81
Study 10561182 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 81
Study 10561182 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all patients)
Number of subjects: 81
Study 10561182 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 lesion
Number of subjects: 81
Study 8686827 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed cricoid pressure
Number of subjects: 120
Study 8686827 — intervention group
Group type: COMPARATOR
Intervention: Two-handed cricoid pressure
Number of subjects: 120
Study 1909607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (RTS)
Number of subjects: 0
Study 6373482 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 1865
Study 6373482 — intervention group
Group type: COMPARATOR
Intervention: copper-T-200
Number of subjects: 1865
Study 31573928 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site support
Number of subjects: 194
Study 31573928 — intervention group
Group type: COMPARATOR
Intervention: Remote support
Number of subjects: 194
Study 30630790 — intervention group
Group type: EXPERIMENTAL
Intervention: Yousiyue (Drospirenone and Ethinylestradiol tablets) plus comprehensive nursing intervention program
Number of subjects: 150
Study 30630790 — intervention group
Group type: COMPARATOR
Intervention: General routine nursing and treatment (Control)
Number of subjects: 150
Study 25689059 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 76
Study 25689059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise
Number of subjects: 76
Study 25689059 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 76
Study 25689059 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 76
Study 24798080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice and physical activity intervention
Number of subjects: 117
Study 21917733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 60
Study 21917733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 60
Study 21917733 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (IVC)
Number of subjects: 60
Study 21108390 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (2.5-10 mg/day)
Number of subjects: 129
Study 21108390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 16973667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 10 weeks (groups 1 and 2)
Number of subjects: 45
Study 16973667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 45
Study 15877268 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct wrist arthro MRI
Number of subjects: 125
Study 11871208 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted professional interventions
Number of subjects: 48000
Study 11871208 — intervention group
Group type: EXPERIMENTAL
Intervention: Organisational interventions (e.g., central computerised tracking systems, nurses contacting patients)
Number of subjects: 48000
Study 11871208 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education added to professional and organisational interventions
Number of subjects: 48000
Study 11871208 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced role of nurses in patient-oriented interventions
Number of subjects: 48000
Study 11245034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracarotid infusion of papaverine and BCNU (250 mg)
Number of subjects: 155
Study 7698589 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg daily)
Number of subjects: 84
Study 7698589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 2693114 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 1070142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline
Number of subjects: 58
Study 1070142 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 58
Study 31081656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study 31625252 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoid energy therapy (HET)
Number of subjects: 30
Study 31625252 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 30
Study 26319710 — intervention group
Group type: EXPERIMENTAL
Intervention: couple-based HIV counseling and testing (HIV-CT) intervention
Number of subjects: 330
Study 26319710 — intervention group
Group type: EXPERIMENTAL
Intervention: relationship-focused HIV counseling and testing (HIV-CT) intervention
Number of subjects: 330
Study 26319710 — intervention group
Group type: COMPARATOR
Intervention: standard individual HIV counseling and testing (HIV-CT)
Number of subjects: 330
Study 26493786 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 267
Study 26493786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 23540599 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic video
Number of subjects: 10
Study 23540599 — intervention group
Group type: COMPARATOR
Intervention: Neutral video
Number of subjects: 10
Study 21635995 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (levodopa 200 mg/benserazide 50 mg)
Number of subjects: 24
Study 21635995 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (branded formulation)
Number of subjects: 24
Study 19494555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal monitoring with cardiotocography during labor
Number of subjects: 0
Study 16542275 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoCinch
Number of subjects: 51
Study 16542275 — intervention group
Group type: COMPARATOR
Intervention: Enteryx
Number of subjects: 51
Study 12616141 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive valacyclovir therapy
Number of subjects: 225
Study 11206638 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 100 mg (group A)
Number of subjects: 15
Study 11206638 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg (group B)
Number of subjects: 15
Study 11206638 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 15
Study 9020563 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase activity in serum
Number of subjects: 119
Study 9020563 — intervention group
Group type: COMPARATOR
Intervention: Serum and urine of women with nonneoplastic diseases
Number of subjects: 119
Study 9020563 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-amylase activity in serum
Number of subjects: 119
Study 3703931 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training on the Kinetron exercise machine
Number of subjects: 20
Study 3703931 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic exercise program and gait training (Control)
Number of subjects: 20
Study 30485674 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveys in general surgery and colorectal surgery
Number of subjects: 0
Study 29695590 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg once daily for 1 week, followed by tailored levodopa and/or opicapone dose adjustments
Number of subjects: 495
Study 29695590 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from entacapone to opicapone
Number of subjects: 495
Study 29695590 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term use of opicapone
Number of subjects: 495
Study 29695590 — intervention group
Group type: COMPARATOR
Intervention: Dyskinesia as an adverse event
Number of subjects: 495
Study 26985797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (Eylea) 2 mg every 4 weeks (2q4)
Number of subjects: 1465
Study 26985797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (Eylea) 2 mg every 8 weeks (2q8)
Number of subjects: 1465
Study 26985797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis) 0.5 mg every 4 weeks (Rq4)
Number of subjects: 1465
Study 26985797 — intervention group
Group type: COMPARATOR
Intervention: Fluid status at week 12
Number of subjects: 1465
Study 25392635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine infusion (group I)
Number of subjects: 60
Study 25392635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (group II)
Number of subjects: 60
Study 25392635 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (group III)
Number of subjects: 60
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight at ∼10 wk gestation
Number of subjects: 350
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body water (TBW) at ∼10 wk gestation
Number of subjects: 350
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arm muscle area (UAMA) at ∼10 wk gestation
Number of subjects: 350
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in TBW from ∼10-20 wk
Number of subjects: 350
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight change from ∼10-20 wk
Number of subjects: 350
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gains in weight from 20 to 32 wk
Number of subjects: 350
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gains in UAMA from 20 to 32 wk
Number of subjects: 350
Study 22990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Gains in upper arm fat area (UAFA) from 20 to 32 wk
Number of subjects: 350
Study 20188604 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin G potassium troches (50 mg), applied 4 times per day for 4 days
Number of subjects: 258
Study 20188604 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 258
Study 20188604 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 258
Study 17609907 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling on conventional acupoints plus DU20
Number of subjects: 50
Study 17609907 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling on conventional acupoints plus DU26
Number of subjects: 50
Study 17609907 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling on conventional acupoints plus HT7
Number of subjects: 50
Study 17609907 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling on all three acupoints (DU20, DU26, HT7)
Number of subjects: 50
Study 16055616 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based psychoeducational intervention delivered by a respiratory nurse specialist for 6 months
Number of subjects: 92
Study 16055616 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 11870180 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP (fluorouracil, interferon alpha-2b, and cisplatin)
Number of subjects: 172
Study 11870180 — intervention group
Group type: COMPARATOR
Intervention: M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 172
Study 11870180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FAP and M-VAC
Number of subjects: 172
Study 11870180 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP
Number of subjects: 172
Study 11870180 — intervention group
Group type: COMPARATOR
Intervention: M-VAC
Number of subjects: 172
Study 10219721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus management training (information, relaxation training, therapeutic noise strategy)
Number of subjects: 65
Study 10219721 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-level white noise (LTWN) stimulation
Number of subjects: 65
Study 8557216 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride (TER) 2 mg/day
Number of subjects: 41
Study 8557216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2365462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn12F-DT conjugates (higher-molecular-weight)
Number of subjects: 3
Study 2365462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pn12F-DT conjugates (lower-molecular-weight)
Number of subjects: 3
Study 2365462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Pn12F-DT conjugates
Number of subjects: 3
Study 2365462 — intervention group
Group type: COMPARATOR
Intervention: Pnu-Imune (control)
Number of subjects: 3
Study 377155 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene (Navane)
Number of subjects: 30
Study 377155 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine and chlorpromazine (control)
Number of subjects: 30
Study 31272427 — intervention group
Group type: EXPERIMENTAL
Intervention: Event notifications only
Number of subjects: 0
Study 31272427 — intervention group
Group type: EXPERIMENTAL
Intervention: Event notifications plus a care transitions intervention
Number of subjects: 0
Study 31272427 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0